Boni Elewski
Dermatology · Birmingham, ALNPI 1437192317
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $200,728 of the $270,928 with a category attached, or 74.1%. It is spread thinly across 20 manufacturers, the largest accounting for just 16.4%. Among dermatology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $1193.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$44K
- Novartis$39K
- Boehringer Ingelheim$37K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$32K
- Pfizer$24K
- UCB, Inc.$19K
- plus $76K from 14 others
Across 654 payments — averaging $8259.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$738K
- Amgen$726K
- UCB SA$720K
- Pfizer$643K
- AbbVie$528K
- Novartis$461K
- plus $1.6M from 16 others
What the payments were for
- Consulting fees$200,72874%
- Speaking & faculty fees$43,61916%
- Travel & lodging$20,3107%
- Food & beverage$5,6042%
- Education$6670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 31 | $44,307 |
| Novartis | 30 | $38,588 |
| Boehringer Ingelheim | 16 | $36,661 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 40 | $32,213 |
| Pfizer | 16 | $24,497 |
| UCB, Inc. | 20 | $18,658 |
| Johnson & Johnson | 27 | $17,558 |
| LEO Pharma Inc. | 8 | $16,495 |
| Bristol Myers Squibb | 11 | $12,389 |
| Amgen | 7 | $10,522 |
| E.r. Squibb & Sons, L.L.C. | 6 | $10,207 |
| Sun Pharmaceutical Industries Inc. | 2 | $3,634 |
| Janssen Global Services, LLC | 3 | $2,411 |
| EMD Serono, Inc. | 1 | $1,625 |
| Almirall LLC | 1 | $850 |
| Lilly USA, LLC | 3 | $149 |
| Janssen Scientific Affairs, LLC | 2 | $65 |
| Incyte Corporation | 1 | $53 |
| AbbVie | 1 | $31 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$270,928 in reported general payments places this provider in the 95th percentile of 168 dermatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 90 | $321,614 |
| TremfyaGuselkumab | 16 | $206,848 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $206,534 |
| Humira(Cf) PenAdalimumab | 16 | $179,658 |
| OtezlaApremilast | 28 | $115,795 |
| RinvoqUpadacitinib | 17 | $102,692 |
| Fluocinonide | 19 | $1,077 |
| Azelaic Acid | 15 | $1,075 |
| Clindamycin Phosphate | 25 | $989 |
| Dutasteride | 30 | $932 |
| Ketoconazole | 48 | $898 |
| Doxycycline Hyclate | 25 | $817 |
| Doxycycline Monohydrate | 32 | $737 |
| Hydroxychloroquine Sulfate | 28 | $661 |
| Triamcinolone Acetonide | 33 | $508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $17,558 | $206,84816 claims |
| AmgenOtezla | $10,522 | $115,79528 claims |
| AbbVieRinvoq | $31 | $102,69217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 168 dermatology providers in Alabama.
Other dermatology in Birmingham
- James KrellBirmingham$944K
- Julie HarperBirmingham$920K
- Corey HartmanBirmingham$573K
- Tiffany MayoBirmingham$256K
- Kristy CurlBirmingham$158K
- Sarah Lauren HugheyBirmingham$143K
- Megan CherryBirmingham$137K
- Ann HillBirmingham$56K
- Lauren GrahamBirmingham$45K
- Stacy HaynesBirmingham$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.